Fries C, Ji L, Devidas M, Rabin KR, Loh ML, Lee LW, Kirsch I, Teachey DT, Gupta S, Wood BL, Rau RE. Minimal residual disease by high-throughput sequencing in standard risk-favorable pediatric B-lymphoblastic leukemia. Blood Adv. 2026 Sep 8;10(17):6027-6031. doi: 10.1182/bloodadvances.2026020975. PMID: 42348788; PMCID: PMC13558236.
Publication Citation
Abstract
Most children with B-lymphoblastic leukemia (B-ALL) are cured by modern chemotherapy immunotherapy, but their burden of treatment-related toxicity underscores a need to further refine risk-adapted therapy. Prognostic advances from frontline incorporation of blinatumomab1 have stimulated interest in testing whether carefully selected, favorable-risk groups might safely benefit from chemotherapy deescalation. The responsible design of such studies requires a clear understanding of how all prognostic information should inform eligibility.